Ariflo COPD Long-Term Efficacy Studies Should Use Active Controls – Cmte.

15 Sep 2003
News

The Pink Sheet pinkeditor@informa.com

Executive Summary

GlaxoSmithKline's long-term efficacy studies for Ariflo in chronic obstructive pulmonary disease should be designed as non-inferiority trials with active controls, members of FDA's Pulmonary-Allergy Drugs Advisory Committee suggested Sept. 5

Existing Subscriber? Sign in to continue reading.

New to Pink Sheet? Start a free trial today!

Table
View full table

ASK THE ANALYST
Email

Print
Bookmark
Share

Tags:

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

PS042448

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

PS042448

All set! This article has been sent to my@email.address.

All fields are required. For multiple recipients, separate email addresses with a semicolon.

Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.

Ariflo COPD Long-Term Efficacy Studies Should Use Active Controls – Cmte.

News

Executive Summary

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

Register

Ask The Analyst

Email Article

Ariflo COPD Long-Term Efficacy Studies Should Use Active Controls – Cmte.

News

Executive Summary

Related Content

Quarterly Call Round-Up: Pfizer, GSK, Lilly Updates

Quarterly Call Round-Up: Pfizer, GSK, Lilly Updates

October User Fee Lineup Includes 7 NMEs; Many Expect “Approvable” Action

October User Fee Lineup Includes 7 NMEs; Many Expect “Approvable” Action

GSK Ariflo Long-Term Efficacy Trials Needed For COPD Approval – FDA Cmte.

GSK Ariflo Long-Term Efficacy Trials Needed For COPD Approval – FDA Cmte.

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

Register

Ask The Analyst

Email Article

Sign In To Set a Search Alert